Cost-effectiveness of IGRA/QFT-Plus for TB screening of migrants in Oman

Int J Infect Dis. 2020 Mar:92S:S72-S77. doi: 10.1016/j.ijid.2020.03.010. Epub 2020 Mar 18.

Abstract

Objective: To estimate the cost of a screening program for identifying latent tuberculosis (TB) infections in migrants to Oman.

Methods: A Markov model was used to estimate the cost of screening using an interferon-gamma release assay (IGRA) applied to all migrants from high TB endemic countries, followed by preventive TB treatment.

Results: The model compared seven different scenarios, with a comparison of the direct cost and the quality-adjusted life-years (QALYs) saved.

Conclusions: IGRA testing followed by 3 months of preventive treatment with rifapentine/isoniazid (3HP) was the most cost-effective intervention.

Keywords: Cost; DAILYs; Latent tuberculosis; Screening.

MeSH terms

  • Cost-Benefit Analysis
  • Female
  • Humans
  • Interferon-gamma Release Tests / economics*
  • Isoniazid / therapeutic use
  • Latent Tuberculosis / diagnosis*
  • Latent Tuberculosis / economics
  • Markov Chains
  • Mass Screening
  • Oman
  • Quality-Adjusted Life Years
  • Rifampin / analogs & derivatives
  • Rifampin / therapeutic use
  • Transients and Migrants*
  • Tuberculosis / prevention & control

Substances

  • Isoniazid
  • Rifampin
  • rifapentine